Navigation Links
Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
Date:1/8/2013

Boston, MA (PRWEB) January 08, 2013

The U.S. Food and Drug Administration (FDA) approved JUXTAPID™ (lomitapide), a new, first-in-class treatment option for clinical management of patients with homozygous familial hypercholesterolemia (HoFH) on December 28, 2012. The FDA decision prompted the Cardiometabolic Health Congress (CMHC) expert faculty to examine the implications this new treatment option may have on physician practice and patient care.

HoFH, an inherited genetic disorder caused by a mutation to the LDL receptor, is associated with early onset of atherosclerosis and premature cardiac death. Patients with HoFH tend to respond poorly to statin therapy because of low LDL receptor activity. For patients with HoFH who do not respond to statin therapy, LDL apheresis is indicated. This approach is expensive, invasive, and not universally available or effective alone – many patients do not achieve target LDL-C levels and as many as 30 percent of pediatric patients receiving long-term LDL apheresis progress to atherosclerotic disease of the coronary arteries and/or aorta.

Daniel Rader, MD, Cooper-McClure Professor of Medicine and Pharmacology and chief of the Division of Translational Medicine and Human Genetics in the Department of Medicine, the Perelman School of Medicine at the University of Pennsylvania, stated, “The magnitude of LDL-C and apoB reduction seen with lomitapide in patients with HoFH is substantially greater than that achieved with any other pharmacologic therapies in this disease and is expected to change the course of the disease and delay the onset and progression of atherosclerotic cardiovascular disease.”

For patients with HoFH, heart and vascular disease often develop in childhood, and the average age of death is approximately 30 years. For this reason, Robert H. Eckel, MD, co-chair of th
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Midwest Healthcare Startups Raise $996 Million in 2012
2. HealthEconomics.Com Appoints New Director of Information Technology and Operations
3. Join Cato BioVentures and Cancer Advances at Biotech Showcase 2013 & J.P. Morgan 31st Annual Healthcare Conference
4. BulletinHealthcare a TOP 10 “Most Innovative Company” of 2012 According to Pharma Marketing Publication PM360
5. First Maryland Hospital Offering 3D Mammograms? VA Maryland Health Care System
6. Opedix® Kinetic Health Gear Unveils New KNEE-Tec™ Knee Support Tights Shown to Reduce Quadriceps Muscle Fatigue and Knee Pain
7. The Medzilla Employment Report for December, 2012: Unemployment Drops to Lowest Rate in 4 Years; Experts Predict Unprecedented Growth in Healthcare IT
8. Life Solutions Advocates Announces New Partnerships in Health Promotion and Disease Prevention Initiative
9. Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Feature Rising Trend in Pharma Price Cuts to Secure Reimbursement
10. Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference
11. Analysis of Venture Capital Investment Trends in the North American and European Healthcare Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: ... $1.7 million which brings Q3 orders to $5.8 million and provides ... control projects in North America and one ... continue to bid new projects at record levels," said Peter ... were higher at the end of Q3 than they have been ...
(Date:10/20/2014)... Oct. 20, 2014  GenVec, Inc. (NASDAQ: GNVC ... , Ph.D., from its board of directors effective on October ... 2003, and served as its chairman from June 2006 to ... Nominating and Corporate Governance and Audit Committees of the board.  ... a decade of dedicated service to GenVec, and its stockholders," ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
(Date:10/20/2014)... OR (PRWEB) October 20, 2014 Local ... participate in an investigational study of donor stem cells ... in stem cell therapy and has performed clinical stem ... this study is to determine if a single injection ... affected joints can help reduce pain and inflammation in ...
Breaking Biology Technology:Zola P. Horovitz To Retire From GenVec Board 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Calif., Aug. 7 ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), ... 2008. ISTA reported net revenue of $17.8 million for the,quarter ... quarter of 2007.,The net loss for the second quarter ended ... compared with a net loss of $8.7 million (or $0.32,per ...
... /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ("Chromos" or the ... arrangement agreement (the "Arrangement Agreement") dated,August 6, 2008 ... subsidiary of Chromos, and Modatech Systems Inc. ("Modatech"),pursuant ... agreed to effect a plan,of arrangement (the "Arrangement") ...
... in Health Sciences and Photonics, today announced that its analytical ... Food Safety Monitoring (BFSM) in a mobile laboratory supporting the ... for volatile organic compounds in beverages and pesticides in food ... ...
Cached Biology Technology:ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 2ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 3ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 4ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 5ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 6ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 7Chromos enters into an Arrangement Agreement 2Chromos enters into an Arrangement Agreement 3 PerkinElmer Expertise and Solutions Integral to Food Safety Monitoring for the Beijing Games : Methods, Applications Expertise and Instrumentation Deployed in Mobile Laboratory 2 PerkinElmer Expertise and Solutions Integral to Food Safety Monitoring for the Beijing Games : Methods, Applications Expertise and Instrumentation Deployed in Mobile Laboratory 3
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... and Washington land managers have a new synthesis of ... moist mixed-conifer (MMC) forests in the two states. ... in Eastern Oregon and Washington: A Synthesis of the ... a general technical report published by the U.S. Forest ... to a request from managers for a synthesis of ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... using highly sophisticated equipment. Yet the Florida State University geochemist ... Tibet and camping in the foothills of the Himalayas ... that unique mix of skills, Wang was chosen to take ... prehistoric woolly rhino ever found. A paper describing the team,s ...
... WASHINGTON, D.C. The American Association for Cancer ... Science of Cancer Health Disparities from Sept. 18-21, 2011, ... This conference will bring together scientists, survivors, ... cancer genetics, epidemiology and treatment methods to better meet ...
... pheromone-baited bucket traps, canines to sniff out breeding sites, ... the coconut rhinoceros beetle (CRB) on Guam with the ... tactics. USDA has given Guam an infusion of cash ... population on island. Aubrey Moore, entomologist and researcher with ...
Cached Biology News:A wild and woolly discovery: FSU scientist's Tibetan expedition ends with prehistoric find 2A wild and woolly discovery: FSU scientist's Tibetan expedition ends with prehistoric find 3AACR to host conference on the science of cancer health disparities 2
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
... platform, 220 V, is used for agitation and ... cultures, staining and destaining of gels and blots, ... control (8-40 rpm) and can handle a maximum ... features two 29 x 21 cm platforms covered ...
... 2,2′-Azino- bis (3-ethylbenzthiazoline-6-sulfonic Acid) Clear ... of ABTS and H 2 O 2 ... stabilizers. Peroxidase substrate that is soluble, safe, convenient ... ™ develops intense blue-green color that can ...
...
Biology Products: